Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Preparation method of capecitabine molecularly imprinted sustained and controlled release material doped with poss and mcm-41-mps

A technology of MCM-41-MPS and capecitabine, which can be used in medical preparations with non-active ingredients, medical preparations containing active ingredients, organic active ingredients, etc., and can solve problems such as molecular recognition characteristics with limited effects

Active Publication Date: 2021-03-19
TIANJIN MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The effectiveness of MIPs is limited by their modest molecular recognition properties compared to natural antibodies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of capecitabine molecularly imprinted sustained and controlled release material doped with poss and mcm-41-mps
  • Preparation method of capecitabine molecularly imprinted sustained and controlled release material doped with poss and mcm-41-mps
  • Preparation method of capecitabine molecularly imprinted sustained and controlled release material doped with poss and mcm-41-mps

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] In order to confirm the effect of POSS and MCM-41-MPS on the imprinting effect of monolithic columns, we prepared different molecularly imprinted monolithic columns, one was MIP doped with POSS and MCM-41-MPS, and the control group was doped with POSS MIP, MIP doped with MCM-41-MPS and regular MIP. Through high-performance liquid phase analysis results, the specific operation steps are as follows:

[0035] Preparation steps:

[0036] First, the template molecule CAP (1.80%) and the initiator AIBN (0.57%) were dissolved in the binary porogen DMSO (31.06%) and [BMIM]BF 4 (32.87%), and then POSS (0.26%) was dissolved in the crosslinker EDMA (27.18%). The two mixtures were mixed and sonicated (5 min), then the binary monomers AAm (0.97%) and AMPS (2.36%) were added and dissolved by sonication. Finally, add MCM-41-MPS (0.26%) and sonicate for 5 minutes to disperse evenly. The pre-polymerization solution was introduced into a stainless steel column (100 × 4.6 mm inner dia...

Embodiment 2

[0041] The effect of hybrid materials on the drug release effect of polymers was studied by in vitro drug release experiments. The results are shown in figure 2 and Table 1.

[0042] Table 1 In vitro drug release data

[0043]

[0044] The results showed that compared with the four groups of polymers, the release time of conventional MIP was the shortest, and the release amount of MIP reached the maximum value of 50 μg at about 4 h. However, the drug release amount of the polymer doped with POSS and MCM-41-MPS was significantly increased to 226 μg, and the drug burst rate was the lowest (3.1%), and the drug release time was also significantly extended to 11 h. This fully demonstrates that POSS and MCM-41-MPS MIP can significantly delay the release time of capecitabine, and have a good slow and controlled release effect on the drug.

Embodiment 3

[0046] The drug release effect of the optimal formula POSS&MCM-41-MPS MIP and the control group (ie POSS&MCM-41-MPS NIP and CAP commercial drugs) were compared through pharmacokinetic experiments in rats. The results are shown in image 3 .

[0047] The results showed that the optimal formulation POSS&MCM-41-MPS MIP had the longest peak time (4h) and the largest peak area (483.7 ng h / mL), while the conventional MIP had the smallest peak time and peak area. Comparing the relative bioavailability, the relative bioavailability of different drug-loaded materials is quite different. The relative bioavailability of the best formulation was the highest, 173.4%, while the relative bioavailability of conventional MIP was the lowest, 72.5%. The relative bioavailability of AMPS MIP and AAm MIP in the control group were 99.4% and 83.0%, respectively. These results fully proved that the use of AAm and AMPS as binary monomers does have an impact on the drug release effect of the drug-loade...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a preparation method for an integrated POSS and MCM-41-MPS doped capecitabine molecularly-imprinted sustained-release or controlled-release material, specifically to the preparation method and performance evaluation of a capecitabine molecularly-imprinted sustained-release or controlled-release material doped by POSS and the mesoporous molecular sieve MCM-41. Results showthat due to the existence of both POSS and MCM-41-MPS, the selective recognition ability and adsorption performance of a molecularly-imprinted polymer can be significantly improved, better imprintingeffect is generated, and certain influence is performed on the specific surface area and pore size distribution of the polymer. Hybrid MIP is used as a carrier material of capecitabine, and in-vitro and in-vivo drug release experiment results prove that an optimal formula is significantly prolonged in drug release time and significantly improved in relative bioavailability (wherein F is 173.4%), so great research significance and practical value are achieved when the hybrid MIP is applied to the sustained-release or controlled-release material of the capecitabine.

Description

technical field [0001] The invention relates to a preparation method of a capecitabine molecularly imprinted slow-release material doped with POSS (polyhedral oligomeric silsesquioxane) and MCM-41-MPS, specifically doped polyhedral oligomeric silsesquioxane Preparation method and performance evaluation of capecitabine molecularly imprinted sustained and controlled release materials of oxane and mesoporous molecular sieve MCM-41. Background technique [0002] Molecular imprinting technology is an "artificial lock" technology that can identify "molecular keys". Through the assembly of template molecules and functional monomers, molecularly imprinted polymers (MIPs) that are complementary to the target molecular structure can be formed in molecular imprinting. Due to the stability and stability of antibody mimics, MIPs outperform natural receptors and thus can be used in extreme environments. MIP has good application prospects in the fields of environment, medicine and food b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K47/34A61K31/7068A61K47/32A61K47/04A61P35/00C08F222/14C08F220/58C08F220/56C08F230/08
CPCA61K31/7068A61K47/02A61K47/32A61K47/34A61P35/00C08F222/1006C08F222/102C08F220/585C08F220/56C08F230/08
Inventor 黄艳萍杨芳芳刘照胜
Owner TIANJIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com